Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
GBA2
Introduction
GBA2 is the gene that encodes the enzyme non-lysosomal glucosylceramidase in humans.[1][2] It has glucosylceramidase (EC 3.2.1.45) activity.
Function
Function
This gene encodes a microsomal beta-glucosidase that catalyzes the hydrolysis of bile acid 3-O-glucosides as endogenous compounds. Studies to determine subcellular localization of this protein in the liver indicated that the enzyme was mainly enriched in the microsomal fraction where it appeared to be confined to the endoplasmic reticulum. This putative transmembrane protein is thought to play a role in carbohydrate transport and metabolism.[2]
See also
See also
References
References
- ↑ Matern H, Boermans H, Lottspeich F, Matern S (Oct 2001). “Molecular cloning and expression of human bile acid beta-glucosidase”. J Biol Chem. 276 (41): 37929–33. doi:10.1074/jbc.M104290200. PMID 11489889.
- ↑ 2.0 2.1 “Entrez Gene: GBA2 glucosidase, beta (bile acid) 2”.
Further reading
Further reading
- Land A, Braakman I (2001). “Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum”. Biochimie. 83 (8): 783–90. doi:10.1016/S0300-9084(01)01314-1. hdl:1874/5091. PMID 11530211.
- Feizi T, Larkin M (1992). “AIDS and glycosylation”. Glycobiology. 1 (1): 17–23. doi:10.1093/glycob/1.1.17. PMID 2136376.
- Boot RG, Verhoek M, Donker-Koopman W, et al. (2007). “Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2”. J. Biol. Chem. 282 (2): 1305–12. doi:10.1074/jbc.M610544200. PMID 17105727.
- Wolk T, Schreiber M (2007). “N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization”. Med. Microbiol. Immunol. 195 (3): 165–72. doi:10.1007/s00430-006-0016-z. PMID 16547752.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). “The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC)”. Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Humphray SJ, Oliver K, Hunt AR, et al. (2004). “DNA sequence and analysis of human chromosome 9”. Nature. 429 (6990): 369–74. doi:10.1038/nature02465. PMC 2734081. PMID 15164053.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). “Complete sequencing and characterization of 21,243 full-length human cDNAs”. Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
- Pantophlet R, Wilson IA, Burton DR (2003). “Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design”. J. Virol. 77 (10): 5889–901. doi:10.1128/JVI.77.10.5889-5901.2003. PMC 154011. PMID 12719582.
- Hart ML, Saifuddin M, Spear GT (2003). “Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin”. J. Gen. Virol. 84 (Pt 2): 353–60. doi:10.1099/vir.0.18734-0. PMID 12560567.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Nagase T, Kikuno R, Nakayama M, et al. (2001). “Prediction of the coding sequences of unidentified human genes. XVIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro”. DNA Res. 7 (4): 273–81. doi:10.1093/dnares/7.4.271. PMID 10997877.
- Matern H, Heinemann H, Legler G, Matern S (1997). “Purification and characterization of a microsomal bile acid beta-glucosidase from human liver”. J. Biol. Chem. 272 (17): 11261–7. doi:10.1074/jbc.272.17.11261. PMID 9111029.
- Papandreou MJ, Fenouillet E (1997). “Effect of various glycosidase treatments on the resistance of the HIV-1 envelope to degradation”. FEBS Lett. 406 (1–2): 191–5. doi:10.1016/S0014-5793(97)00273-1. PMID 9109416.
- Bolmstedt A, Sjölander S, Hansen JE, et al. (1996). “Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response”. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12 (3): 213–20. doi:10.1097/00042560-199607000-00001. PMID 8673525.
- Yeh JC, Seals JR, Murphy CI, et al. (1993). “Site-specific N-glycosylation and oligosaccharide structures of recombinant HIV-1 gp120 derived from a baculovirus expression system”. Biochemistry. 32 (41): 11087–99. doi:10.1021/bi00092a019. PMID 8218172.
- Fenouillet E, Jones I, Powell B, et al. (1993). “Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain”. J. Virol. 67 (1): 150–60. PMC 237347. PMID 8093218.
- Montefiori DC, Robinson WE, Mitchell WM (1988). “Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1”. Proc. Natl. Acad. Sci. U.S.A. 85 (23): 9248–52. doi:10.1073/pnas.85.23.9248. PMC 282716. PMID 3264072.
- Blough HA, Pauwels R, De Clercq E, et al. (1987). “Glycosylation inhibitors block the expression of LAV/HTLV-III (HIV) glycoproteins”. Biochem. Biophys. Res. Commun. 141 (1): 33–8. doi:10.1016/S0006-291X(86)80330-8. PMID 3099781.